Homeopathic Claims Pose Continuing FTC/FDA Regulatory Conflict
This article was originally published in The Rose Sheet
Executive Summary
FTC shuts down the second marketer this year for making fraudulent claims for human chorionic gonadotropin weight-loss products. Enforcing against other homeopathics’ claims that violate advertising regulations, however, is on hold until FTC resolves its differences with FDA’s oversight of the category.
You may also be interested in...
GAO Memory Supplement Review Recalls FDA's Regulatory Challenges
GAO recommends better cooperation between FDA and FTC and more public outreach are key to preventing consumers from believing noncompliant cognitive benefit claims for supplements.
FTC Settles Big With Sensa, Other Weight-Loss Marketers
FTC settles with Sensa products and three other weight-loss product marketers, and launches its “gut check” voluntary media partnership program to prevent bogus claims. A firm cited in FTC’s 2011 investigation of human chorionic gonadotropin product ads also reached a settlement with the agency.
Science-Based Evaluation Advocates Want Tighter Homeopathic Oversight
Public health concerns should prompt FDA to tighten its regulation of homeopathic drugs, a citizen petition filed by the nonprofit Center for Inquiry says.